- Policy
- Introduction-development-turn, and the price reduction
- by Kim, Jung-Ju Dec 6, 2019 09:46am
- The pharmaceutical industry's reaction to the ambitious post-evaluation of the high-priced drugs, ambitiously issued by the government and insurance authorities, is cold. The pharmaceutical community understood the big direction of follow-up of drugs for rational fiscal expenditure, coupled with enhanced security. At the same time, it is a ma
- Company
- Xolair reimbursed in China, Concerns over Korea Passing
- by Kim, Jin-Gu Dec 6, 2019 09:46am
- Novartis' Xolair is listed as a reimbursed drug in China. Analysts say that 'Korea Passing' is a reality in the industry Xolair, a chronic rash treatment drug, has been cited as one of the leading examples of Korea Passing, 'withholding or withdrawal of reimbursement in Korea to be listed in China and other countries'. China's Nation
- Company
- High-risk osteoporosis should increase bone formation first
- by Eo, Yun-Ho Dec 6, 2019 09:43am
- “For a high-risk patient, it would be better to use effective bone-forming agent from the beginning.” Amgen Korea held a press conference held on Dec. 4 for the launch of Evenity (romosozumab-aqqg), where Chair Chung Ho-yeon of Korean Society for Bone and Mineral Research (KSBMR) stressed on the importance of top-down style prescription
- Policy
- Investing KRW 4 tn fostering Biohealth as ‘Post-semiconduct
- by Kang, Shin-Kook Dec 6, 2019 09:43am
- Until 2025, the Korean government is to assertively invest four trillion won on fostering biohealth industry as a ‘post-semiconductor industry.’ On Dec. 4, Deputy Prime Minister Hong Nam-ki led the fifth Innovative Growth Strategy meeting and the 28th Economic Ministerial meeting and discussed about next generation innovative growth engine
- Company
- 3rd PARP inhibitor Talzenna readies for Korean market
- by Eo, Yun-Ho Dec 6, 2019 09:39am
- A pharmaceutical industry source reported on Dec. 6 that Pfizer Korea has recently submitted an application to Ministry of Food and Drug Safety (MFDS) for an approval on PARP inhibitor Talzenna (talazoparib). When it gets the green light from the ministry, it would be the third PARP inhibitor medicine in Korea to enter the market, followi
- Policy
- “Providing as much clinical information for patients”
- by Lee, Tak-Sun Dec 5, 2019 06:23am
- Since the end of last October, the Korean Ministry of Food and Drug Safety (MFDS) has expanded scope of information on approved investigation new drug’s (IND) protocol uploaded on its website. Previously, only the names of clinical trial, sponsoring client, IND, targeting disease and clinical trial institute were publicly disclosed, but
- Policy
- Forxiga, solvate modifier applied for the first permit
- by Lee, Tak-Sun Dec 5, 2019 06:22am
- Domestic pharmaceutical companies have developed a solvate modified drug for the SGLT-2 inhibitory diabetic drug Forxiga (Dapagliflozin, AstraZeneca Korea) and has entered into the application process. Once approved, the market sale will be available from April 8 2023, when material patents will be terminated. According to the MFDS on 3
- Opinion
- Both to blame of the rising Pharmaceuticals & Korea
- by Eo, Yun-Ho Dec 5, 2019 06:16am
- The pharmaceutical industry is a high value-added industry and Korea is now more interested in new drugs than ever before. As interest has increased, the names of pharmaceutical companies that have reported news such as clinical failures, discontinuations, or controversy about efficacy are very popular on the Internet. It is possible. S
- Policy
- HIRA unveils listed drug reevaluation guideline
- by Kim, Jung-Ju Dec 5, 2019 06:14am
- The government unveiled the details of the post-marketing reevaluation criteria and procedure of reimbursed drug. The scope of listed drug reevaluation mainly centers expensive drug items, such as anticancer and rare disease treatments, covered by insurance benefit despite their uncertainty in clinical efficacy. The evaluation borrows
- InterView
- The key to drug development is not just safety and efficacy
- by Jung, Hye-Jin Dec 5, 2019 06:12am
- “In short, it is an area that is easy to miss even though it is important enough to be the core of new drug development. Most of the domestic companies that have applied for a permit with the US FDA or the European EMA are asked to submit additional data. As more and more pharmaceutical companies are attempting to penetrate overseas, Korean
